Related Experiment Video
Updated: May 19, 2026
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
Inhibitory effect of hexahydrocurcumin on human platelet aggregation
Huei-Ping Dong1, Rei-Cheng Yang, I-Chun Chunag
1Department of Physical Therapy, Fooyin University, Kaohsiung, Taiwan.
Natural Product Communications
|August 23, 2012
Summary
Hexa-curcumin effectively inhibited adenosine diphosphate (ADP)-induced human platelet aggregation. This finding suggests its potential as a therapeutic agent to prevent atherosclerosis in people.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiovascular Research
Background:
- Platelet aggregation plays a crucial role in the development of atherosclerosis.
- Understanding compounds that can modulate platelet activity is vital for cardiovascular disease prevention.
Purpose of the Study:
- To investigate the inhibitory effects of hexa-curcumin on human platelet aggregation.
- To explore the potential of hexa-curcumin as an anti-atherosclerogenic agent.
Main Methods:
- Human platelet-rich plasma was treated with hexa-curcumin.
- Adenosine diphosphate (ADP)-induced platelet aggregation was measured.
Main Results:
- Hexa-curcumin demonstrated a significant inhibitory effect on ADP-induced platelet aggregation.
- The compound reduced the aggregation response of human platelets.
Conclusions:
- Hexa-curcumin possesses anti-platelet activity.
- Hexa-curcumin shows promise as a potential therapeutic agent for preventing atherosclerosis.
